APVO
Price:
$0.282
Market Cap:
$2.66M
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO44...[Read more]
Industry
Biotechnology
IPO Date
2016-07-20
Stock Exchange
NASDAQ
Ticker
APVO
According to Aptevo Therapeutics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -384230.00. This represents a change of -92.65% compared to the average of -5227072.31 of the last 4 quarters.
The mean historical Enterprise Value of Aptevo Therapeutics Inc. over the last ten years is 64.04M. The current -384230.00 Enterprise Value has changed -160.00% with respect to the historical average. Over the past ten years (40 quarters), APVO's Enterprise Value was at its highest in in the March 2015 quarter at 165.43M. The Enterprise Value was at its lowest in in the September 2023 quarter at -9383920.76.
Average
64.04M
Median
47.78M
Minimum
-9293634.44
Maximum
158.25M
Discovering the peaks and valleys of Aptevo Therapeutics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Enterprise Value = 158.25M
Minimum Annual Increase = -114.27%
Minimum Annual Enterprise Value = -9293634.44
Year | Enterprise Value | Change |
---|---|---|
2023 | -9293634.44 | 660.35% |
2022 | -1222277.44 | -114.27% |
2021 | 8.57M | -92.33% |
2020 | 111.71M | 198.13% |
2019 | 37.47M | 117.62% |
2018 | 17.22M | -83.19% |
2017 | 102.43M | 76.32% |
2016 | 58.09M | -63.05% |
2015 | 157.20M | -0.66% |
2014 | 158.25M | Infinity% |
The current Enterprise Value of Aptevo Therapeutics Inc. (APVO) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-650285.19
5-year avg
29.45M
10-year avg
64.04M
Aptevo Therapeutics Inc.’s Enterprise Value is less than Kronos Bio, Inc. (14.20M), less than Cyclerion Therapeutics, Inc. (2.56M), less than Larimar Therapeutics, Inc. (453.31M), less than Addex Therapeutics Ltd (11.85M), greater than Achilles Therapeutics plc (-48532901.00), less than Nutriband Inc. (0), less than Quoin Pharmaceuticals, Ltd. (57.98M), less than Longeveron Inc. (3.24M), less than RenovoRx, Inc. (20.39M), less than Virax Biolabs Group Limited (13.20M), less than Passage Bio, Inc. (5.49M), less than Magenta Therapeutics, Inc. (38.72M), greater than TRACON Pharmaceuticals, Inc. (-114170976.00), greater than Invivyd, Inc. (-6133696.00), greater than Avenue Therapeutics, Inc. (-39784910.00), greater than Hoth Therapeutics, Inc. (-1770008.00), greater than Revelation Biosciences, Inc. (-3469351.00), greater than NeuroBo Pharmaceuticals, Inc. (-8886223.00), greater than null (-6292396.00),
Company | Enterprise Value | Market cap |
---|---|---|
14.20M | $57.28M | |
2.56M | $7.14M | |
453.31M | $483.02M | |
11.85M | $18.06M | |
-48532901.00 | $42.12M | |
0 | $64.53M | |
57.98M | $2.86M | |
3.24M | $31.02M | |
20.39M | $24.95M | |
13.20M | $8.86M | |
5.49M | $37.34M | |
38.72M | $42.44M | |
-114170976.00 | $136.30K | |
-6133696.00 | $107.42M | |
-39784910.00 | $3.15M | |
-1770008.00 | $6.14M | |
-3469351.00 | $3.19M | |
-8886223.00 | $21.47M | |
-6292396.00 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptevo Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aptevo Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Aptevo Therapeutics Inc.'s Enterprise Value?
What is the highest Enterprise Value for Aptevo Therapeutics Inc. (APVO)?
What is the 3-year average Enterprise Value for Aptevo Therapeutics Inc. (APVO)?
What is the 5-year average Enterprise Value for Aptevo Therapeutics Inc. (APVO)?
How does the current Enterprise Value for Aptevo Therapeutics Inc. (APVO) compare to its historical average?